menu
    • menu
    [{"orgOrder":0,"company":"AstraZeneca","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"MEDI-578","moa":"Beta-nerve growth factor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ MedImmune","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ MedImmune"},{"orgOrder":0,"company":"Levicept","sponsor":"Hammersmith Medicines Research | MAC Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"LEVI-04","moa":"Neurotrophin pathway","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Levicept","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Levicept \/ Hammersmith Medicines Research | MAC Clinical Research","highestDevelopmentStatusID":"6","companyTruncated":"Levicept \/ Hammersmith Medicines Research | MAC Clinical Research"},{"orgOrder":0,"company":"Haoma Medica","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Naquinate","moa":"Osteoclast","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Haoma Medica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haoma Medica \/ Parexel","highestDevelopmentStatusID":"6","companyTruncated":"Haoma Medica \/ Parexel"},{"orgOrder":0,"company":"Haoma Medica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Naquinate","moa":"Osteoclast","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Haoma Medica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haoma Medica \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Haoma Medica \/ Undisclosed"},{"orgOrder":0,"company":"Haoma Medica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Naquinate","moa":"Osteoclast","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Haoma Medica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haoma Medica \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Haoma Medica \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Solution","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AstraZeneca

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            AstraZeneca

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MEDI7352

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI7352 in Healthy Volunteers

                            Details : MEDI7352 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Osteoarthritis, Knee.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 25, 2021

                            Lead Product(s) : MEDI7352

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Haoma Medica

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Haoma Medica

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naquinate

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Haoma Medica Completes First-in-Human Trial for NaQuinate

                            Details : The first-in-human trial initiated last year in healthy adults studied single and multiple doses of NaQuinate. The primary objective was to assess the safety, tolerability and pharmacokinetics.

                            Product Name : Osteopura

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 26, 2020

                            Lead Product(s) : Naquinate

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Haoma Medica

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Haoma Medica

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naquinate

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Haoma Medica to Present Scientific Data on NaQuinate, a Potential New Treatment for Osteoporosis, at ASBMR 202...

                            Details : NaQuinate synergized the body’s normal response to loading to generate significant increases in cortical bone mass (increased cross sectional area, reductions in cortical porosity) and J-score (predictor of bone strength) compared to loading alone.

                            Product Name : Osteopura

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 11, 2020

                            Lead Product(s) : Naquinate

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Haoma Medica

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Haoma Medica

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naquinate

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Parexel

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of NaQuinate in Healthy Volunteers

                            Details : Naquinate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Osteoporosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 30, 2019

                            Lead Product(s) : Naquinate

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Parexel

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Levicept

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Levicept

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LEVI-04

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Hammersmith Medicines Research | MAC Clinical Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Tolerability & Pharmacokinetics of LEVI-04 in Healthy Volunteers and Patients With Osteoarthritis Knee...

                            Details : LEVI-04 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Osteoarthritis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 24, 2017

                            Lead Product(s) : LEVI-04

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Hammersmith Medicines Research | MAC Clinical Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            GSK

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            GSK

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Denosumab

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            China HVT Safety, PK, PD

                            Details : Denosumab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Osteoporosis.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            May 12, 2014

                            Lead Product(s) : Denosumab

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            AstraZeneca

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            AstraZeneca

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MEDI-578

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Assess MEDI -578 in Patients With Osteoarthritis (OA) of the Knee

                            Details : MEDI-578 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Osteoarthritis.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            February 22, 2010

                            Lead Product(s) : MEDI-578

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth